En route to San Diego to attend the 2022 Alzheimer’s Association International Conference (AAIC)

Looking forward to hearing perspectives from thought leaders who will do a deep dive on ongoing AD trials and key trends shaping the Alzheimer field. 

I am excited to reconnect with many different folks across the Alzheimer field and looking forward to my dear friend and colleague Dr Susan Abushakra, Azheon‘s Chief Medical Officer (https://alzheon.com/) podium presentation on the 

• Effects of Oral ALZ 801, an Amyloid Oligomer Inhibitor on Plasma Biomarkers in APOE4 Carriers with Early AD: Results of Six-month interim analysis for a Phase 2 Biomarker Study.
• ALZ801 development strategy https://clinicaltrials.gov/ct2/show/NCT04770220
• Update on ongoing Phase 3 ALZ 801 trial https://apolloe4.researchstudytrial.com/ and path to New Drug Application.

If you or your F&F are struggling with memory loss and interested in learning more about Alzheimer Disease and an investigational late stage trial of a tablet that could potentially slow the progression of Alzheimer, please check out  https://clinicaltrials.gov/ct2/show/NCT04770220 and/or APOLLOE4.com

Read more: https://clinicaltrials.gov/ct2/show/NCT04770220